Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer.

Saudi Pharm J · 2019 · PMC6438706 · PMID 30976180

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

The interim overall survival (OS) analysis showed a trend favoring apalutamide, as the median OS was 39 months in the placebo arm and was not reached in the apalutamide arm; HR = 0.70, p = 0.07.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.